PiaSky® (crovalimab) Dosing & Administration

Treatment on your patients’ terms: PiaSky® can be taken at home once every 4 weeks1-3

The initial PiaSky® loading dose is one IV infusion, administered by a healthcare provider. The next 4 loading doses are subcutaneous injections, given once per week. Maintenance doses are then administered once every 4 weeks subcutaneously, with no further IV infusions required. Patients can self-inject PiaSky® after the initial loading dose and after receiving training from their healthcare provider.

PiaSky® offers your patients a different way to administer their treatment, by allowing subcutaneous self-injections outside of a healthcare setting.

Product photo
PiaSky dosing schedule showing an initial IV infusion, followed by weekly subcutaneous injections, then ongoing maintenance injections every four weeks.

Administer PiaSky® doses based on body weight3

Body Weight

40 kg to <100 kg

≥100 kg

Loading Dose

Day 1

1000 mg (IV)

1500 mg (IV)

Day 2, 8, 15, 22

340 mg (SC)

340 mg (SC)

Maintenance Dose

Day 29 and Q4W thereafter

680 mg (SC)

1020 mg (SC)

Dosing & Administration

Patients can self-inject their PiaSky® maintenance doses subcutaneously within minutes, once prepared³˒⁴

How to train your patients or their caregivers to prepare and administer subcutaneous injections for PiaSky®

The initial PiaSky® loading dose is an IV infusion, administered by a healthcare provider.1

 


PiaSky® is prepared and administered in a series of simple steps5

Preparing the injection


Administering PiaSky®


How do you ensure that patients are properly trained for subcutaneous self-administration of PiaSky?

syringe-pink

By training your patients to self-administer their PiaSky® injections, you may help empower them to take treatment into their hands.³˒⁶*

*Patients starting PiaSky® will receive an initial weight-based loading dose through IV infusion. Four subsequent loading doses are then given weekly by subcutaneous injection. Weight-based maintenance dosing is then administered once every 4 weeks subcutaneously. Patients may self-inject after receiving training from their healthcare provider.
IV = intravenous; Q4W = 4-weekly; SC = subcutaneous.

Card Image

Why PiaSky®

A C5 inhibitor in a subcutaneous injection can help give PNH patients their lives back.

See How
Card Image

PiaSky® Efficacy

Learn more about results with PiaSky® in treatment-naïve and switch trials.

See The Data
References
  1. Röth A, et al. Am J Hematol. 2024;99:1768–1777.
  2. Scheinberg P, et al. Am J Hematol. 2024;99:1757–1767.
  3. PiaSky® (crovalimab) 170mg/mL solution for injection Summary of Product Characteristics. F. Hoffmann-La Roche; 2024.
  4. Rӧth A, et al. Blood. 2020;135:912–920.
  5. PiaSky® (crovalimab) 170mg/mL solution for injection Package Leaflet. F. Hoffmann-La Roche; 2024.
  6. Overton P, et al. Patient Prefer Adherence 2021:15:811–834.